Berns et al. found that the loss of the ARID1A gene could activate the expression of Annexin A1 (ANXA1), and then activate the AKT pathway to enable breast cancer cells to obtain trastuzumab resistance during adjuvant therapy. This evidence concerns the gene ANXA1 and breast cancer.